Precision Medicine and Biologics

What is Upcoming in Precision Medicine?
June 06, 2022

Darrell S. Rigel, MD, MS, FAAD, answers the question of what is up coming in the world of dermatology in the way of precision medicine.

Mindera Health Pilot Program to Improve Psoriasis Management
May 24, 2022

Mindera Health and a national health insurance company launched a pilot program to improve moderate-to-severe psoriasis management with precision medicine.

Precision Medicine Test for Psoriasis Predicts Response Rate to Biologics
May 24, 2022

Recent data tracks the first realization of precision medicine for patients with psoriasis.

POLL: Are You Looking Forward to More Bio-similars on the Market?
May 23, 2022

Click here to answer this weeks poll.

Biosimilars for Humira Are on Their Way
May 20, 2022

In 2023 as many as 11 biosimilars to Humira are headed for the US market.

Amgen Releases Positive Phase 3 Results for Stelara Biosimilar
April 19, 2022

A phase 3 study conducted by Amgen found that the company’s ustekinumab biosimilar was as safe and efficacious as the reference product (Stelara) in patients with moderate to severe plaque psoriasis.

Optimize Off-Label Use of Biologics and New Medications
March 27, 2022

Experts explored out-of-the-box solutions for treating challenging skin and hair disorders at the American Academy of Dermatology (AAD)’s 2022 Annual Meeting held March 25 to 29, 2022, in Boston, Massachusetts.

Dupilumab Receives FDA Priority Review and Accepts sBLA for Children 6 Months to 5 Years
February 10, 2022

If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate to severe atopic dermatitis for young children 6 months to 5 years old.

Biologics Offer Range of Options for Dermatologists Looking to Treat Patients
January 16, 2022

Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.

Secukinumab Receives FDA Approval for Pediatric Patients with PsA
December 23, 2021

Secukinumab is the only biologic treatment in the US that’s approved by the FDA for pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).